GH Stock Forecast & Price Target

Guardant Health is experiencing a robust financial trajectory, with a two-year revenue CAGR projected at +28% from 2023 to 2025, supported by expansion in colorectal cancer (CRC) and other indications, as well as new product launches. The company's recent approval of the Shield liquid biopsy for colorectal cancer screening contributed to surpassing revenue estimates, leading to increased annual revenue guidance reflecting approximately 31% year-over-year growth for 2025. Additionally, Guardant's successful rollout of Reveal, its fastest-growing oncology test, coupled with strategic initiatives to secure reimbursement for breast cancer testing, positions the company favorably for continued financial success and market cap growth.

Guardant Health's medium-term revenue guidance for its newly launched Shield product has been perceived as underwhelming, which raises concerns about its future financial performance. The company's adjusted EBITDA loss of $45.5 million in the third quarter of 2025 highlights ongoing profitability issues and may instigate caution among investors, particularly if faced with any negative news concerning regulatory, reimbursement, or product launch timelines. Furthermore, the potential for a lack of compelling data and regulatory challenges could hinder the company's expansion plans outside the United States, reinforcing uncertainties around its long-term growth trajectory.